Kintor Pharma announced the results of a phase II clinical trial of pyrilutamide (KX-826) for treating adult female androgenetic alopecia (AGA). More news from Innovent Biologics, InnoBM Pharmaceuticals.
The Hong Kong Stock Exchange (HKEX) announced that it has accepted an IPO application from Boan Biotech.
Fosun Pharma announced yesterday that its subsidiary Gland Pharma intend to acquire Cenexi Group, a European CDMO company, for a consideration not exceeding EUR 210 million.
Full-Life Technologies announced that it has signed an agreement to acquire Focus-X Therapeutics to expand its radiopharmaceuticals pipeline.
Sirona Biochem announced that it has signed an expanded international agreement with Wanbang Biopharmaceuticals to collaborate on licensing TFC-039, Sirona’s SGLT2 inhibitor, for treating both animals and humans. More news from Fosun Kite.
PrimeLink and Xiling Lab, two ADC drug discovery companies, have just closed financing rounds. More news from Hengrui Pharma, Blueprint Medicines, CStone.
ViroTech Pharmaceutical has received a strategic investment of RMB 100 million from NKY Medical. NKY will hold 10.42% of ViroTech’s shares after the investment is completed.
JS InnoPharm announced today that it inked an agreement with Strategia Holdings to found JSI Ventures (JSV), a Boston-based company that will integrate the companies’ R&D efforts. More news from NOVAST Laboratories.
Umoja Biopharma and IASO Biotherapeutics announced that they have entered a research agreement to evaluate Umoja’s iCIL platform with IASO’s chimeric antigen receptors (CARs). More news from Harbour BioMed, Dragonfly Therapeutics.